Lista de obras - Maarten Boers - Dominio Público Uruguay

A Smartphone App for Self-Monitoring of Rheumatoid Arthritis Disease Activity to Assist Patient-Initiated Care: Protocol for a Randomized Controlled Trial

artículo científico publicado en 2020

A novel method to combine assessment of benefit and harm: OMERACT 3x3 methodology applied to two active comparator trials.

artículo científico publicado en 2018

A reference case for economic evaluations in osteoarthritis: an expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)

artículo científico publicado en 2014

Adaptive Trial Designs in Rheumatology: Report from the OMERACT Special Interest Group

scientific article published on 15 February 2019

Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study

artículo científico publicado en 2022

Balneotherapy for osteoarthritis

artículo científico publicado en 2007

Balneotherapy for rheumatoid arthritis ⬇️

artículo científico publicado el 1 de enero de 2003

Cardiovascular Event Risk in Rheumatoid Arthritis Compared with Type 2 Diabetes: A 15-year Longitudinal Study

scientific article published on 15 May 2019

Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease

artículo científico publicado en 2016

Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology

artículo científico publicado en 2019

Designing effective graphs to get your message across

scholarly article by Maarten Boers published 10 May 2018 in Annals of the Rheumatic Diseases

Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0.

artículo científico

Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay

scientific article published on 01 January 2019

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

artículo científico publicado en 2014

Effects of Co-medication with Glucocorticoids in Biologics Trials

artículo científico publicado en 2018

Exploration, Development, and Validation of Patient-reported Outcomes in Antineutrophil Cytoplasmic Antibody-associated Vasculitis Using the OMERACT Process

artículo científico publicado en 2015

Feasibility of Self-Monitoring Rheumatoid Arthritis With a Smartphone App: Results of Two Mixed-Methods Pilot Studies

scientific article published on 21 September 2020

Graphics and statistics for cardiology: designing effective tables for presentation and publication

artículo científico publicado en 2017

Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative

artículo científico publicado en 2019

Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology

artículo científico publicado en 2019

Long-term Glucocorticoid Use in Rheumatoid Arthritis

artículo científico publicado en 2020

Mortality has improved in RA, but we must remain vigilant. Response to: 'Early intensive treatment normalises excess mortality in ACPA-negative RA but not in ACPA-positive RA' by Matthijssen et al

scientific article published on 08 July 2019

Normal mortality of the COBRA early rheumatoid arthritis trial cohort after 23 years of follow-up

artículo científico publicado en 2019

OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies

scientific article published on 15 February 2019

Patient global assessment to define remission in rheumatoid arthritis:quo vadis?

artículo científico publicado en 2020

Population characteristics as important contextual factors in rheumatological trials: an exploratory meta-epidemiological study from an OMERACT Working Group

scientific article published on 30 June 2020

Public/private partnerships, at what price?

scientific article published on 04 May 2020

Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia

artículo científico publicado en 2016

Response to: 'Tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: data from the STRASS study' by Marotte et al

artículo científico publicado en 2019

Response to: Comment on l'Ami et al titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial' by den Broeder et al.

artículo científico publicado en 2017

Safety of Abatacept Versus Placebo in Rheumatoid Arthritis: Integrated Data Analysis of Nine Clinical Trials

scientific article published on 29 May 2019

Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial.

artículo científico publicado en 2017

The Added Value of Radiographs in Diagnosing Knee Osteoarthritis Is Similar for General Practitioners and Secondary Care Physicians; Data from the CHECK Early Osteoarthritis Cohort

artículo científico publicado en 2020

The OMERACT-OARSI Core Domain Set for Measurement in Clinical Trials of Hip and/or Knee Osteoarthritis ⬇️

Towards consensus in defining and handling contextual factors within rheumatology trials: an initial qualitative study from an OMERACT working group

scientific article published on 14 October 2020

Uptake of the OMERACT-OARSI Hip and Knee Osteoarthritis Core Outcome Set: Review of Randomized Controlled Trials from 1997 to 2017

scientific article published on 01 March 2019

Lista de obras de Maarten Boers

A Smartphone App for Self-Monitoring of Rheumatoid Arthritis Disease Activity to Assist Patient-Initiated Care: Protocol for a Randomized Controlled Trial

A novel method to combine assessment of benefit and harm: OMERACT 3x3 methodology applied to two active comparator trials.

A reference case for economic evaluations in osteoarthritis: an expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)

Adaptive Trial Designs in Rheumatology: Report from the OMERACT Special Interest Group

Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study

Balneotherapy for osteoarthritis

Balneotherapy for rheumatoid arthritis ⬇️

Cardiovascular Event Risk in Rheumatoid Arthritis Compared with Type 2 Diabetes: A 15-year Longitudinal Study

Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease

Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology

Designing effective graphs to get your message across

Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0.

Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Effects of Co-medication with Glucocorticoids in Biologics Trials

Exploration, Development, and Validation of Patient-reported Outcomes in Antineutrophil Cytoplasmic Antibody-associated Vasculitis Using the OMERACT Process

Feasibility of Self-Monitoring Rheumatoid Arthritis With a Smartphone App: Results of Two Mixed-Methods Pilot Studies

Graphics and statistics for cardiology: designing effective tables for presentation and publication

Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative

Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology

Long-term Glucocorticoid Use in Rheumatoid Arthritis

Mortality has improved in RA, but we must remain vigilant. Response to: 'Early intensive treatment normalises excess mortality in ACPA-negative RA but not in ACPA-positive RA' by Matthijssen et al

Normal mortality of the COBRA early rheumatoid arthritis trial cohort after 23 years of follow-up

OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies

Patient global assessment to define remission in rheumatoid arthritis:quo vadis?

Population characteristics as important contextual factors in rheumatological trials: an exploratory meta-epidemiological study from an OMERACT Working Group

Public/private partnerships, at what price?

Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia

Response to: 'Tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: data from the STRASS study' by Marotte et al

Response to: Comment on l'Ami et al titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial' by den Broeder et al.

Safety of Abatacept Versus Placebo in Rheumatoid Arthritis: Integrated Data Analysis of Nine Clinical Trials

Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial.

The Added Value of Radiographs in Diagnosing Knee Osteoarthritis Is Similar for General Practitioners and Secondary Care Physicians; Data from the CHECK Early Osteoarthritis Cohort

The OMERACT-OARSI Core Domain Set for Measurement in Clinical Trials of Hip and/or Knee Osteoarthritis ⬇️

Towards consensus in defining and handling contextual factors within rheumatology trials: an initial qualitative study from an OMERACT working group

Uptake of the OMERACT-OARSI Hip and Knee Osteoarthritis Core Outcome Set: Review of Randomized Controlled Trials from 1997 to 2017